REFERENCE TITLE: controlled substances; approved medications

 

 

 

State of Arizona

Senate

Fifty-third Legislature

First Regular Session

2017

 

 

SB 1377

 

Introduced by

Senator Brophy McGee

 

 

AN ACT

 

Amending section 36‑2511, Arizona Revised Statutes; Amending title 36, chapter 27, article 2, Arizona Revised Statutes, by adding section 36‑2517; relating to controlled substances.

 

 

(TEXT OF BILL BEGINS ON NEXT PAGE)

 


Be it enacted by the Legislature of the State of Arizona:

Section 1.  Section 36-2511, Arizona Revised Statutes, is amended to read:

START_STATUTE36-2511.  Nomenclature

The controlled substances listed or to be listed in the schedules in sections 36‑2512, through 36‑2513, 36‑2514, 36‑2515, 36‑2516 and 36‑2617 are included by whatever official, common, usual, chemical or trade name designated. END_STATUTE

Sec. 2.  Title 36, chapter 27, article 2, Arizona Revised Statutes, is amended by adding section 36-2517, to read:

START_STATUTE36-2517.  United States food and drug administration; approved medication

Any compound, mixture or preparation that contains cannabidiol and that is approved by the United States food and drug administration and rescheduled by the United States drug enforcement administration is a controlled substance for the purposes of this chapter and may be prescribed in this state. END_STATUTE

Sec. 3.  Intent

The legislature finds that both children and adults with epilepsy are in desperate need of new treatment options and that cannabidiol is showing potential as one of these treatments.  If a cannabidiol medication is approved by the United Stated food and drug administration and rescheduled by the United States drug enforcement administration, patients should have rapid access to this treatment option.  The availability of this new prescription medication is intended to augment, not to restrict or otherwise amend, other cannabinoid treatment modalities currently available under state law.

Sec. 4.  Applicability

This act does not affect anything authorized or prohibited by title 36, chapter 28.1, Arizona Revised Statutes.

Sec. 5.  Conditional enactment; notice

A.  This act does not become effective unless on or before January 1, 2021 a cannabidiol investigational product is newly approved as a prescription medication pursuant to 21 United States Code section 360bb and 21 United States Code section 355 and is controlled under a federal interim final rule issued pursuant to 21 United States Code section 811(j) and published in the federal register.

B.  The executive director of the Arizona state board of pharmacy shall notify in writing the director of the Arizona legislative council on or before July 1, 2021 either:

1.  Of the date on which the condition was met.

2.  That the condition was not met.

Sec. 6.  Short title

This act may be cited as "The Pediatric Epilepsy Treatment Act of 2017".